Clinical trial
Safety and Efficacy of Repeated Intravitreal Administration of Vascular…
NCT00320788 · Regeneron Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00320788 |
|---|---|
| Title | Safety and Efficacy of Repeated Intravitreal Administration of Vascular Endothelial Growth Factor (VEGF) Trap in Patients With Wet Age-Related Macular Degeneration (AMD) |
| Official title | A Randomized, Controlled Study of the Safety, Tolerability and Biological Effect of Repeated Intravitreal Administration of VEGF Trap in Patients With Neovascular Age-Related Macular Degeneration |
| Lead sponsor | Regeneron Pharmaceuticals, Industry |
| Collaborators | Bayer Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Macular Degeneration |
| Intervention type | Biological |
| Interventions | aflibercept injection (VEGF Trap-Eye, BAY86-5321) |
| Enrollment | 159 |
| Start date | Apr 1, 2006 |
| Primary completion | Jun 1, 2008 |
| Completion | Aug 1, 2008 |
| First posted | May 3, 2006 |
| Last update posted | Mar 1, 2012 |
| Countries | United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: